JPRN-UMIN000015971已完成2 期
A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer. - A phase II study of Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.
Sairtama Breast Cancer Clinical Study Group (SBCCSG)0 个研究点目标入组 51 人开始时间: 2015年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)having systemic infection with a fever of 38 degrees or more 2)protocol treatment of drug, and a history of hypersensitivity to the solvent 3)patients with brain metastases in need of treatment to the brain hypertension and emergency brain radiation 4)patients with following serious complication ischaemic heart disease or heart disease such as arrhythmia not controllable by treatment myocardial infarction < 6 months prior to study entry hepatic cirrhosis interstitial pneumonia or pulmonary fibrosis bleeding tendency Uncontrolable hypertension Uncontrolable proteinuria 5)having active double cancer 6)patients with a history of radiation therapy to the measurable lesions 7)history of mental disorder, a central nervous system damage, and cerebral blood vessel neuropathy 8)pregnancy, breast-feeding or women with childbearing potential 9)patients undergoing continuous systemic administration of steroids 10)HBs antigen is positive 11)judged by the investigator not to be appropriate for the study
研究者
相似试验
招募中
4 期
Observational study of paclitaxel with Bevacizumab for advanced or recurrent breast cancer(SBCCSG-28)advanced or recurrent breast cancerJPRN-UMIN000009090Saitama Breast Cancer Clinical Study Group (SBCCSG)70
已完成
2 期
Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung canceron-small-cell lung cancerJPRN-UMIN000004573First Department of Internal Medicine, Shinshu University School of Medicine42
招募中
2 期
A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapyarge cell neuroendocrine carcinoma (LCNEC)JPRN-UMIN000011713Toho University Omori Medical Center19
进行中（未招募）
不适用
Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer.Patients with locally advanced, non metastatic, resectable primary rectal cancer stage cT3 or cT4 who are subject to combined chemotherapy of the pelvic region in the pre-operative setting.MedDRA version: 14.1Level: PTClassification code 10038038Term: Rectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000802-30-ITROCHE
进行中（未招募）
不适用
Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal CancerEUCTR2005-001012-41-ITROCHE